Abstract
Background Pathological remodelling of native vascular smooth muscle cells (VSMC) within the arterial wall is a key contributor to vascular disease. A driver of this remodelling is platelet-derived growth factor BB (PDGF-BB) and its signalling via activation of the calcium ion channel, ORAI1. Here, we investigated if there are associations of ORAI1 polymorphisms with human cardiovascular disease.
Methods and results We conducted candidate gene association analysis and revealed that a missense ORAI1 variant (rs3741596, S218G) associates with an increased risk of hospital-diagnosed peripheral vascular disease, generalised atherosclerosis, acute ischaemic heart disease, and atrioventricular and left bundle-branch block in White British UK Biobank participants. Rs3741596 is also associated with higher circulating platelet counts and reduced total triglyceride levels. Functional analysis of the effects of rs3741596 S218G variant on ORAI1 channel function, via introduction of the S218G ORAI1 variant in HEK293 cells using CRISPR/Cas9 and investigation of its effects on SOCE, showed significantly enhanced SOCE compared to wild type cells, suggesting that the S218G variant enhances ORAI1 function.
Conclusions Our results reveal an association between an ORAI1 missense variant and occlusive vascular diseases. These findings provide a novel insight into the role of ORAI1 in vascular remodelling and highlight its potential as a treatment target for vascular pathologies.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Not applicable
Funding Statement
This work was supported by the British Heart Foundation grant (FS/18/12/33270) to MB and DB, a British Heart Foundation student scholarship (FS/17/66/33480) to HS, a Medical Research Council studentship to KN (MR/N013840/1), personal support from King Saud University, Riadh to AA, Leeds Cardiovascular Endowment support to CC, an Alfonso Martín Escudero Foundation postdoctoral grant to GR-G and a National Institute for Health Research Academic Clinical Fellowship to FS and the James Ellis Charitable Trust to MB.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UK Biobank.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data is provided in the supplementary materials online.
